Best Price API Powder 99% CAS 1257044-40-8 Venetoclax, Abt199

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Yellow Powder
• Purity: >99%
• Model NO.: Frazer-Venetoclax
• Grade: Pharmaceutical Grade
• Appearance: Yellow Powder
• CAS No: 1257044-40-8
• Shelf Life: 2 Years
• Test Method: HPLC
• Application: Health Care Supplements
• Form: Powder
• Storage: Store Cool Dry Place
• Shipping Methods: DHL, FedEx, TNT, EMS, UPS, etc
• Shipping Area: Worldwide/All Countries
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

Best Price API Powder 99% CAS 1257044-40-8 Venetoclax, Abt199

 

Specification of Analysis

Items	Standards		Results
Appearance	White or off-white solid powder		Complies
Identification	By IR		Complies
	By HPLC		Complies
Loss on Drying	≤ 1.00%		0.80%
Heavy Metals	≤ 20ppm		Complies
Residue on Ignition	≤ 0.10%		0.06%
Relative Substance	Any single impurity: ≤0.20%		Complies
	Total Impurities: ≤1.00%		0.28%
Purity(by HPLC)	≥ 99.0%		99.72%
Assay                  (on the anhydrous basis)	98.0%~102.0%		99.54%
Reference Standard	In-house Standard
Conclusion	The product complied to In-house standard.
Storage	Preserve in tight,light-resistant containers in a cool place

 

What is Venetoclax?

ABT-199 is a white powder, Venetoclax, also known as ABT-199 or GDC0199, ABT-199 is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. ABT-199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.

Function of Venetoclax

ABT-199 is a small molecule oral drug that treats chronic lymphocytic leukemia (CLL) in those with a specific chromosomal abnormality.In 2015, the United States Food and Drug Administration (FDA) granted Breakthrough Therapy Designation to venetoclax for subjects with CLL who have relapsed or have been refractory to previous treatment and have the 17p deletion genetic mutation.
 

Application of Venetoclax

ABT-199 is a white powder, Venetoclax, also known as ABT-199 or GDC0199, ABT-199 is an orally bioavailable, selective small molecule inhibitor of the anti-apoptotic protein Bcl-2, with potential antineoplastic activity. ABT-199 mimics BH3-only proteins, the native ligands of Bcl-2 and apoptosis activators, by binding to the hydrophobic groove of Bcl-2 proteins thereby repressing Bcl-2 activity and restoring apoptotic processes in tumor cells.